Long-term effects of a house dust mite sublingual immunotherapy tablet in an environmental exposure chamber trial.

[1]  D. Bernstein,et al.  Efficacy of house dust mite sublingual immunotherapy tablet in North American adolescents and adults in a randomized, placebo-controlled trial. , 2016, The Journal of allergy and clinical immunology.

[2]  J. Virchow,et al.  Efficacy of a House Dust Mite Sublingual Allergen Immunotherapy Tablet in Adults With Allergic Asthma: A Randomized Clinical Trial. , 2016, JAMA.

[3]  J. Larsen,et al.  Fractionation of Source Materials Leads to a High Reproducibility of the SQ House Dust Mite SLIT-Tablets , 2016, International Archives of Allergy and Immunology.

[4]  V. Backer,et al.  Effective treatment of house dust mite-induced allergic rhinitis with 2 doses of the SQ HDM SLIT-tablet: Results from a randomized, double-blind, placebo-controlled phase III trial. , 2016, The Journal of allergy and clinical immunology.

[5]  Allan Linneberg,et al.  Respiratory allergy caused by house dust mites: What do we really know? , 2015, The Journal of allergy and clinical immunology.

[6]  D. Bernstein,et al.  Onset and dose-related efficacy of house dust mite sublingual immunotherapy tablets in an environmental exposure chamber. , 2015, The Journal of allergy and clinical immunology.

[7]  H. Malling,et al.  Prolonged efficacy of the 300IR 5-grass pollen tablet up to 2 years after treatment cessation, as measured by a recommended daily combined score , 2015, Clinical and Translational Allergy.

[8]  V. Backer,et al.  SQ house dust mite sublingually administered immunotherapy tablet (ALK) improves allergic rhinitis in patients with house dust mite allergic asthma and rhinitis symptoms. , 2015, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[9]  G. Canonica,et al.  Standardized quality (SQ) house dust mite sublingual immunotherapy tablet (ALK) reduces inhaled corticosteroid use while maintaining asthma control: a randomized, double-blind, placebo-controlled trial. , 2014, The Journal of allergy and clinical immunology.

[10]  P. Demoly,et al.  Rhinitis , sinusitis , and upper airway disease Efficacy and safety of sublingual tablets of house dust mite allergen extracts in adults with allergic rhinitis , 2016 .

[11]  G. Marks,et al.  Allergen-Specific IL-5 Responses in Early Childhood Predict Asthma at Age Eight , 2014, PloS one.

[12]  S. Durham,et al.  Rhinitis , sinusitis , and upper airway disease SQ-standardized sublingual grass immunotherapy : Confirmation of disease modification 2 years after 3 years of treatment in a randomized trial , 2012 .

[13]  C. Akdis,et al.  Immunological mechanisms of allergen‐specific immunotherapy , 2011, Allergy.

[14]  P. Devillier,et al.  The allergen challenge chamber: a valuable tool for optimizing the clinical development of pollen immunotherapy , 2011, Allergy.

[15]  A. Buist,et al.  Geographical variations in the prevalence of atopic sensitization in six study sites across Canada , 2010, Allergy.

[16]  S. Spector,et al.  Allergen immunotherapy: a practice parameter third update. , 2007, The Journal of allergy and clinical immunology.

[17]  M. Kogevinas,et al.  Geographical variation in the prevalence of positive skin tests to environmental aeroallergens in the European Community Respiratory Health Survey I , 2007, Allergy.

[18]  P. Gergen,et al.  Prevalences of positive skin test responses to 10 common allergens in the US population: results from the third National Health and Nutrition Examination Survey. , 2005, The Journal of allergy and clinical immunology.